Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 2, 2000, Pages 177-181

  Merimsky, Ofer ^a   Meller, Isaac ^a   Flusser, Gidon ^a   Kollender, Yehuda ^a   Issakov, Josephine ^a   Weil Ben Arush, Miriam ^b   Fenig, Eyal ^c   Neuman, Gad ^d   Sapir, Dov ^e   Ariad, Shmuel ^f   Inbar, Moshe ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e HAEMEK MEDICAL CENTER   (Israel)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Angiosarcoma; Bone sarcoma; Gemcitabine; Leiomyosarcoma; Soft tissue sarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOFT TISSUE SARCOMA;

EID: 0033952086     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050027     Document Type: Article

References (10)

1. 1. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105
2. 2. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 7: 347-353
3. 3. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535
4. 4. FDA (1995) Quality of life matters! News section. Ann Oncol 6: 854
5. 5. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ (1995) Schedule dependent antitumor effect of gemcitabine in vivo model system. Semin Oncol 22: 42
6. 6. Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM (1993) The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 68: 52
7. 7. Merimsky O, Meller I, Kollender Y, Inbar M (1998) Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer 34: 1296
8. 8. Malawer MM, Link MP, Donaldson SS (1997) Sarcoma of bones. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, pp 1731-1852
9. 9. Patel SR, Jenkins J, Papadopoulos NE, Burgess NA, Plager C, Pisters PWT, Feig K, Hunt K, Pollack A, Zagars G, Pollock R, Benjamin RS (1999) Preliminary results of a two-arm phase 2 trial of gemcitabine (Gem) in patients (Pts) with gastrointestinal leiomyosarcoma and other soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 18: 541a
10. 10. Spith-Schwalbe E, Koschuth A, Grunewald R, Genvresse I, Possinger K (1998) Gemcitabine in pretreated patients with advanced STS: preliminary results from a phase II trial. Proc Am Soc Clin Oncol 17: A1976